23, "Lianhua Qingdian 'out of stock' after the price increase, some pharmacies selling price increased by more than 50%" of the news on the hot search.
There are media reports that some pharmacies have raised the price of Lianhua Qingdian capsule to different degrees. Among them, 0.35g * 48 capsules / box specifications of Lianhua Qingdian capsule price increase significantly. There is a pharmacy located in Heyuan City, Guangdong Province, the current 0.35g * 48 capsules / box specifications of Lianhua Qingdian capsule price of 46 yuan / box. If the previous about 30 yuan / box of the general price calculation, has increased the price of more than 50%.
For the reason of the price increase, the report said, a pharmacy staff said, "Lianhua Qingdian recently is the price increase, the recent buyers are particularly large. Pricing on the manufacturer's side has gone up, and the goods can not be ordered, then certainly in the price adjustment." There are also pharmacy employees said, "the price of goods is expensive."
So did Ealing Pharmaceuticals, the maker of Lianhua Qingdian, operate a price hike on the drug in question? Pharmacies significantly increased the price of sales of Lianhua Qingdian is universal?
In this regard, the person in charge of Ealing Pharmaceuticals 23rd responded to the Securities Times - e company reporter said, "the company did not raise the price of drugs related to the plague of Lianhua".
eCompany reporter also contacted an instant digital pharmacy head listed company, the company is currently in the country's 17 cities to establish a network of 351 intelligent pharmacy. The company's relevant person in charge told reporters that the platform's Lianhua Qingdian and other anti-epidemic drugs selling price did not change, and currently did not hear the news of the manufacturer's price increase, the price of the drugs in each pharmacy has fluctuated may be due to different promotions at different times of the day. "In terms of supply, on the whole, the supply of Lianhua Qingdian and other drugs on our platform can be guaranteed, and no out-of-stock phenomenon has been found. Sometimes it is impossible to place an order at night because of restocking in the background, and we will also increase our purchasing and supply efforts."
Ealing Pharmaceuticals released a statement
Recently, market rumors said that some areas of Lianhua Qingdian capsule, Lianhua Qingdian granules sold out of the phenomenon, which is also the background of the "some pharmacies selling price increased by more than 50%" on the hot search.
For this sell out rumors, Ealing Pharmaceuticals relevant person in charge of the previous response to the e-company reporter said, Ealing Pharmaceuticals in the past two years has been doing a series of work to improve production capacity, the current capacity has been significantly improved, the production of Lianhua Qingdian products factory in Shijiazhuang, Beijing, Hengshui, etc., and the production of the basic has not been affected. It also said that the production plan of Ealing Pharmaceuticals is "production by sales", and can be adjusted according to market demand in a timely manner to protect the supply of the market, the current sales are normal.
It is worth mentioning that, in the background of "out of stock" in some areas of Lianhua Qingdian and other products, a number of fake "Lianhua" series of products have appeared on the market recently. In this regard, on November 22nd, Ealing Pharmaceuticals released a statement saying that many products called "Lianhua Qingweng Tea", "Chain Flower Qingweng Tea", "Lotus Qingweng Ointment", "Lotus Qingweng Oral Liquid" and "Lotus Qingweng Tea" have recently appeared on the market. Oral liquid, Lotus Clear Warming Plant Drink and Lotus Clearing Warming Pill, which are not produced, sold or authorized to be produced or sold by Ealing Pharmaceuticals. Ealing Pharmaceuticals said that the above products and the company's production of "Ealing Lianhua Qingdian" (drugs) and subordinate companies produced Lianhua brand "Lianhua Qingfei Tea" (drinks) brand name, packaging, etc., similar or similar, it is very easy to confuse, and has been a major consumer misunderstanding. The brand name and packaging of the "Lianhua Qingfei Tea" (drink) are similar or similar, and it is very easy to be confused, and consumers have already had a significant misunderstanding. Yiling Pharmaceuticals also mentioned that "Lianhua Qingfeng", "Lianhua", "Lianhua Qing" and "Lianhua Qingfei" are trademarks registered by the company in accordance with the law and have obtained the exclusive right to use them. Lianhua Qingfei" is the company's trademark registered in accordance with the law and has obtained the exclusive right to use the trademark, while the design patent of "Lianhua Qingfei Capsules" produced by the company has not been authorized for use by others. The company reserves the right to pursue the legal responsibility of those responsible for the production and sale of counterfeit and confusing products and other infringements of the company's trademark rights and other legitimate rights and interests.
Recently the stock price soared
Ealing Pharmaceuticals main business is the patent innovative Chinese medicine research and development, production and sales, its production and sales of Lianhua Qingdian series of products due to many times to enter the new Crown Pneumonia Diagnostic and Treatment Program and received attention.
It is worth mentioning that, as the producer of Lianhua Qingdian, Ealing Pharmaceuticals has been continuously pursued by funds in the secondary market recently.
Quote data show that at the end of September so far less than two months, Ealing Pharmaceuticals stock price from about 18.8 yuan all the way up. Especially since entering November, along with the amplification of volume, Ealing Pharmaceuticals due to the stock price continued to rise twice issued an unusual announcement, and on November 21 touched a record high of 48.66 yuan / share. However, the last two trading days the stock price has retraced, the latest closing price of 39.99 yuan.
From the point of view of operating results, the first three quarters of this year, Ealing Pharmaceuticals achieved total operating income of 7.946 billion yuan, a year-on-year decline of 2.04%; attributable net profit of 1.414 billion yuan, a year-on-year increase of 15.58%, the deduction of non-net profit of 1.416 billion yuan, a year-on-year increase of 20.60%; of which the Q3 single-quarter, to achieve a total operating income of 2.380 billion yuan, year-on-year increased by 7.41%; mother net profit of 366 million yuan, an increase of 40.92% year-on-year, non-deductible net profit of 365 million yuan, an increase of 49.32% year-on-year.
Divided into products, this year, Ealing Pharmaceuticals produced Lianhua Qingdian and other drugs sales growth is obvious. Announcement disclosure, the first three quarters, Ealing Pharmaceuticals main varieties of Tongshenqi by the epidemic and other factors affecting the income compared to the same period in 2021 there is a slight decline, but Q3 since the cardiovascular and cerebrovascular products show a gradual recovery trend, Q3 single-quarter cardiovascular and cerebrovascular products year-on-year to achieve a small increase; Lianhua Qingzheng due to its treatment of new crown, influenza and colds special product attributes, its revenue in 2021 under the higher base still achieved a year-on-year growth.
After the release of the three-quarterly report, Ealing Pharmaceuticals also attracted a number of institutional investors' research. Talking about the overseas export situation of Lianhua Qingdian, the company said, at present, Lianhua Qingdian has been registered and approved for listing in more than 20 countries and regions, and this year, Lianhua Qingdian still continues last year's better sales trend.